Coherus Oncology, Inc. current report, 31 March 2022

Full document

Business Context and Reporting Period

Company: Coherus BioSciences, Inc. (CHRS)
Filing Type: Form 8-K (Current Report)
Date of Report: March 31, 2022
Event: Creation of a direct financial obligation via the drawdown of a Tranche B Loan.

Key Financial Metrics

This filing reports a specific financing event rather than comprehensive period-end financial statements. Key metrics disclosed include:

  • Loan Drawdown: $100.0 million (Tranche B Loan).
  • Total Facility Size: Up to $300.0 million senior secured term loan facility.
  • Interest Rate: 8.25% plus three-month LIBOR (with a 1.00% LIBOR floor).
  • Repayment Schedule: Five equal quarterly principal payments commencing after the 48-month anniversary of the Tranche A Closing Date (January 5, 2022).
  • Maturity Date: Fifth anniversary of Tranche A Closing Date (January 5, 2027) or October 15, 2025, contingent on the outstanding balance of 1.5% Convertible Senior Subordinated Notes due 2026.

Note: The filing text does not provide clear values for revenue, profit, cash flow, margins, or total liquidity positions outside of the specific loan details.

Material Changes

The primary material change is the funding of the Tranche B Loan on March 31, 2022. This drawdown was conditioned upon the delivery of evidence that the Company repaid all indebtedness outstanding under its 8.2% Senior Convertible Notes due March 2022 in connection with their maturity.

Outlook, Risks, and Contingencies

Future Funding Tranches:

  • Tranche C ($50.0 million): Available at the Company's option between April 1, 2022, and March 17, 2023, subject to FDA approval of a Biologics License Application (BLA) for CHS-007 (toripalimab).
  • Tranche D ($50.0 million): Available at the Company's option between April 1, 2022, and March 17, 2023, subject to FDA approval of a BLA for CHS-201 (ranibizumab biosimilar).
  • Uncommitted Facility: The Company may request an additional uncommitted amount of up to $100.0 million subject to new terms.
Risks and Contingencies:
  • Regulatory Approval: Access to $100.0 million of the committed facility is contingent on FDA approvals for specific product candidates.
  • Interest Rate Benchmark: The interest rate is tied to LIBOR; cessation of LIBOR will trigger a replacement rate based on the secured overnight financing rate.
  • Debt Maturity: The maturity date may accelerate to October 15, 2025, if the Company's 2026 Convertible Notes exceed $50.0 million on October 1, 2025.

Investor Verification Checklist

  • Verify the successful repayment of the 8.2% Senior Convertible Notes due March 2022 as a condition for the Tranche B funding.
  • Monitor the status of FDA BLA applications for CHS-007 (toripalimab) and CHS-201 (ranibizumab biosimilar) to assess eligibility for Tranches C and D.
  • Review the outstanding balance of the 1.5% Convertible Senior Subordinated Notes due 2026 to determine if the debt maturity date accelerates to 2025.
  • Confirm the total debt load and liquidity position by reviewing the most recent 10-Q or 10-K, as this 8-K only details the new loan obligation.